Cell-based neurotrophin treatment supports long-term auditory neuron survival in the deaf guinea pig

JOURNAL OF CONTROLLED RELEASE

卷:198

Article

Gillespie, Lisa N.^1,2  Zanin, Mark P.¹  Shepherd, Robert K.^1,2 

[1] Bion Inst, East Melbourne, Vic 3002, Australia

[2] Univ Melbourne, Dept Med Bion, Melbourne, Vic 3010, Australia

关键词: Deafness;    BDNF;    Cell therapy;    Cell encapsulation;    Cochlear implant;   

DOI  :  10.1016/j.jconrel.2014.11.026

来源: Elsevier

【 摘 要 】

The cochlear implant provides auditory cues to profoundly deaf patients by electrically stimulating the primary auditory neurons (ANs) of the cochlea. However, ANs degenerate in deafness; the preservation of a robust AN target population, in combination with advances in cochlear implant technology, may provide improved hearing outcomes for cochlear implant patients. The exogenous delivery of neurotrophins such as brain-derived neurotrophic factor (BDNF) and neurotrophin-3 is well known to support AN survival in deafness, and cell-based therapies provide a potential clinically viable option for delivering neurotrophins into the deaf cochlea. This study utilized cells that were genetically modified to express BDNF and encapsulated in alginate microspheres, and investigated AN survival in the deaf guinea pig following (a) cell-based neurotrophin treatment in conjunction with chronic electrical stimulation from a cochlear implant, and (b) long-term cell-based neurotrophin delivery. In comparison to deafened controls, there was significantly greater AN survival following the cell-based neurotrophin treatment, and there were ongoing survival effects for at least six months. In addition, functional benefits were observed following cell-based neurotrophin treatment and chronic electrical stimulation, with a statistically significant decrease in electrically evoked auditory brainstem response thresholds observed during the experimental period. This study demonstrates that cell-based therapies, in conjunction with a cochlear implant, shows potential as a clinically transferable means of providing neurotrophin treatment to support AN survival in deafness. This technology also has the potential to deliver other therapeutic agents, and to be used in conjunction with other biomedical devices for the treatment of a variety of neurodegenerative conditions. (C) 2014 Elsevier B.V. All rights reserved.

【 授权许可】

Free